• Regular treatment of asthma in adults and children aged 4 years and older who require combined therapy with a long-acting beta2-adrenergic agonist and an inhaled glucocorticosteroid (ICS).
• For patients inadequately controlled on monotherapy with inhaled glucocorticosteroids.
• For patients adequately controlled on therapy with inhaled glucocorticosteroids and long-acting beta2-adrenergic agonists.
• As an initial maintenance therapy for patients with persistent bronchial asthma, where glucocorticosteroids are indicated to achieve disease control.

This product is included in the Essential Medicines List.